Microbial antigens-loaded myeloma cells enhance Th2 cell proliferation and myeloma clonogenicity via Th2–myeloma cell interaction
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Microbial antigens-loaded myeloma cells enhance Th2 cell proliferation and myeloma clonogenicity via Th2–myeloma cell interaction ; volume:19 ; number:1 ; day:23 ; month:12 ; year:2019 ; pages:1-9 ; date:12.2019
BMC cancer ; 19, Heft 1 (23.12.2019), 1-9, 12.2019
- Urheber
-
Tian, Faqing
Lu, Bo
Chen, Ziren
Liu, Junru
Ji, Delan
Li, Juheng
Tang, Meiqin
Zhu, Wei
Li, Juan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-019-6469-4
- URN
-
urn:nbn:de:101:1-2020032712560340375129
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tian, Faqing
- Lu, Bo
- Chen, Ziren
- Liu, Junru
- Ji, Delan
- Li, Juheng
- Tang, Meiqin
- Zhu, Wei
- Li, Juan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Detection of myeloma cell-derived microvesicles: a tool to monitor multiple myeloma load
RUNX2 promotes the suppression of osteoblast function and enhancement of osteoclast activity by multiple myeloma cells
Allogeneic stem cell transplantation in multiple myeloma
Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells-implications for myeloma bone disease
Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells
Natural killer cells efficiently target multiple myeloma clonogenic tumor cells
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells
CIK Cells and HDAC Inhibitors in Multiple Myeloma
CAR-T cells in multiple myeloma: current status
Accelerated single cell seeding in relapsed multiple myeloma
Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Detection of myeloma cell-derived microvesicles: a tool to monitor multiple myeloma load
RUNX2 promotes the suppression of osteoblast function and enhancement of osteoclast activity by multiple myeloma cells
Allogeneic stem cell transplantation in multiple myeloma
Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells-implications for myeloma bone disease
Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells
Natural killer cells efficiently target multiple myeloma clonogenic tumor cells
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells
CIK Cells and HDAC Inhibitors in Multiple Myeloma
CAR-T cells in multiple myeloma: current status
Accelerated single cell seeding in relapsed multiple myeloma
Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Detection of myeloma cell-derived microvesicles: a tool to monitor multiple myeloma load
RUNX2 promotes the suppression of osteoblast function and enhancement of osteoclast activity by multiple myeloma cells
Allogeneic stem cell transplantation in multiple myeloma
Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells-implications for myeloma bone disease
Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells
Natural killer cells efficiently target multiple myeloma clonogenic tumor cells
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells
CIK Cells and HDAC Inhibitors in Multiple Myeloma
CAR-T cells in multiple myeloma: current status